尿毒清胶囊抗肾纤维化作用及其机制研究
|
摘要
目的:(1)了解中西医对肾纤维化发病机制及其防治措施的研究进展;(2)观察升清泄浊法中药制剂尿毒清胶囊对慢性肾功能衰竭患者临床疗效的同时,重点观察其抗肾纤维化的疗效;(3)探讨尿毒清胶囊抗肾纤维化作用机制,为临床应用提供实验依据。
方法:(1)文献研究:通过查阅大量古代和现代中、西医国内外文献,总结和评价有关肾纤维化的中医、西医发病机制和防治措施研究现状。(2)临床研究:用简单随机化、前瞻性的研究方法,将78例慢性肾功能衰竭患者按1∶1分为治疗组和对照组。治疗组用基本治疗加尿毒清胶囊,对照组为基本治疗加包醛氧淀粉,观察患者主要症状、证候(纳差腹胀,恶心呕吐,神疲乏力,腰膝酸痛,皮肤瘙痒,颜面唇甲少华,肌肤甲错,形寒肢冷,手足心热,浮肿,头晕)和实验室检查指标:血红蛋白(Hb)、红细胞总数(RBC)、血清肌酐(Scr)、尿素氮(BUN)、内生肌酐清除率(Ccr)、血清白蛋白(ALB)、血清总胆固醇(Tch)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、血清层粘蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、透明质酸(HA)等,4周为一疗程,连续治疗两个疗程统计结果。继续追踪治疗至6个月时统计各组因病情加重放弃内科治疗,而改用透析治疗的病例数。(3)实验研究:将体外培养人肾小管上皮细胞(HK-2),分为6组:正常对照组、5%尿毒症血清组、10%尿毒症血清组、5%尿毒清胶囊含药血清组、10%尿毒清胶囊含药血清组和蒙诺组(蒙诺浓度为10~(-6)mmol/L),用MTT法检测细胞增殖、用流式细胞术检测细胞周期、a-平滑肌肌动蛋白(α-SMA)阳性细胞的百分率、用逆转录—聚合酶链反应(RT-PCR)测定结缔组织生长因子mRNA(CTGFmRNA)。
结果:(1)文献研究:中医学没有肾纤维化的表述,但根据其临床表现可归于“水肿”、“关格”、“癃闭”、“虚劳”等病症范畴;在病因病机方面,认为脾肾亏虚是本,湿热壅滞三焦,浊毒内盛、瘀血阻络等为标;治疗上多采用通腑泄浊为主,兼用益气补肾、活血化瘀等法。药物有复方制剂、也有单味药物,还有提取的有效单体成分;作用机制有:抑制参与纤维化细胞的增殖和转分化,抑制致纤维化因子的产生、减少ECM的沉积等,表现出较好的疗效。现代医学认为,肾纤维化涉及到肾固有细胞的激活、增殖,单核巨噬细胞的浸润、炎症介质、细胞因子的产生和分泌,最终导致肾脏正常结构的破坏、细胞外基质的沉积,形成纤维化。上皮—间充质细胞转分化(EMT)在肾纤维化中起重要作用,转化生长因子-β1(TGF-β1)和CTGF是强致肾纤维化因子。从防治措施来讲,寻找抑制参与纤维化细胞的增殖和转分化、抑制致纤维化因子的分泌或拮抗其作用的药物,虽然有些用于临床,但疗效不理想。(2)临床研究:治疗组主要症状总积分、大部分症状单项积分均少于对照组(p<0.05或p<0.01),症状有效率和总体疗效高于对照组(p<0.05或p<0.01);尿毒清胶囊能提高慢性肾功能衰竭
Objective: (1)To review the research advancement on the pathogenesy and the therapy of prevention and cure in renal fiabrosis. (2)To observe the clinical efficacy on chronic renal failure(CRF) and the anti-renal fibrosis effect of Chinese traditional medicine Niaoduqing Capsules(NDQC) by the therapy of tonifying and lifting clear QI and excreting pathogenic QI. (3)To explore the mechanism of action of NDQJN on renal fibrosis.Methods:(1)Literature study:To look up a great deal of internal and foreign research documents about the pathogenesy and the therapy of prevention and cure in TCM and western medicine on renal fiabrosis, and summarize and assess these datas. (2)Clinical research:Seventy-eight patients with CRF were randomly and equally divided into subject group and control group .The subject group was administered by symptomatic treatment medicines and NDQC, and the control group was administered by symptomatic treatment medicines and Oxyamyli tectus Aldehydum(OTA). The cardinal symptoms and laboratory examination indexes were observed . The cardinal symptoms included bad appetite, abdominal distension, nausea and vomiting, lassitude, sore waist or knee, skin pruritus, pale face or lip and nails, squamous and dry skin, cold body and limbs, feverish palms and soles, edema, and dizziness. The laboratory examination items contained haematoglobin(HB), red blood cell number(RBC), serum creatinine(Scr), serum urea nitrogen(BUN), creatinine clearance(Ccr), seralbumin(ALB), total cholesterol(Teh), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), serum laminin(LN), precollagen-III(PC-III) , and hyaluronic acid (HA). These items was respectively determined before administration and after eight weeks. The number of patients with dialysis treatment, because of aggravated patient's condition, was recorded in follow-up four months. (3)Experimental study:Human renal tubular epithelial cells (HK-2) were respectively cultured in six different media. They
were normal control group , 5% uremic serum group, 10% uremic serum group, 5% NDQC serum group, 10% NDQC serum group and Monopril geoup(fosinopril density was 10~6mmol/L). Cell proliferation was measured by methylene blue assay (MTT method). Cell life cycle and the positive cell percentage of a-smooth muscle actin(a-SMA) in every group were evaluated by flow cytometry. Connective tissue growth factor messenger RNA (CTGFmRNA) was detected by reverse transcript ion-polymerase chain reaction(RT-PCR) method.Results: (DReview of publications:There was no the nomenclature 'renal fibrosis' in TCM, but the clinical manifestation of renal fibrosis or CRF was discovered in these diseases such as 'edema' , 'frequent vomiting and dysuria' , 'anuria' , 'asthenia' , 'lumbago' and so on. The etiopathogenisis and pathogenesis of renal fibrosis was summarized as asthenia in origin and state of evil domination in superficiality. The asthenia was mainly due to the deficiency of spleen and kidney, and the state of evil domination mainly included stagnation of damp-heat in triple warmer , turbid toxin in body, obstruction of collaterals by blood stasis. The therapeutic methods of cleaning out FU-organ and excreting turbid pathogen were mainly taken , and tonifying QI and invigorating the kidney were also used at the same time in CRF. The materia medica for CRF contained compound preparation, single pharmaceutical product , and simple substance of effective ingredients extracted. Thier mechanisms of action on renal fibrosis were that they inhibited cell proliferation and transdifferentiation , restrained the production of fibrotic factors, and reduced the deposition of extracellular matrix (ECM) in kidney. TCM had satisfactory curative effect on renal fibrosis. At the viewpoint , the pathogenesy of renal fibrosis related to activation and proliferation of renal cells, infiltration of mononuclear macrophage, production and secretion of mediators of inflammation and cytokines. These resulted in destruction of normal kidney structure and deposition of ECM, and fibrous degeneration finally. Epithelium- mesenchymal transdifferentiation(EMT) was one of important pathogenesies in renal fibrosis. Transforming growth factor-P 1(TGF-0 1 ) and CTGF are important growth factor inducing renal fibrosis. People are researching new methods or medicines to prevent and cure renal fibrosis. They may inhibit cell proliferation and EMT , or prevent these cells from secreting or synthesizing cytokines that results in renal fibrosis. Cytokines antagon are also being studied. Some of these medicines have been
administered in some patients, but their therapeutic effect are dissatisfactory. ?The clinical research:The total score of all symptoms and the single score of most of symptoms were both remarkable fewer in subject group than in control group (p<0. 05 UK p<0. 01) .The curative effect rate of symptom and total effective power were both more higher in subject group than in control group(p<0. 05 or p<0. 01) .The levels of ALB and HDL-C were more higher , and the levels of Tchu TG> BUN> Scr> Ccr> LI^ PC-IIL HA were much lower in subject group than in control group(p<0. 05 or p<0. 01) .NDQC remarkably decreased the number of patients who accepted dialytic medication in six months (p<0. 05). ?Experimental study: (DAbsorbance 490(A490) was remarkably higher in 5% uremic serum group and 10% uremic serum group than in normal control group with use of MTT(p<0.01) ,and that was without significant difference between 5% NDQC serum group and 5% uremic serum group (p>0. 05) , and that was much lower both in 10% NDQC serum group and in monopril group than in 5% uremic serum group (both p<0. 01) .No significant difference of A490 was found among 5% NDQC serum group, 10% NDQC serum group, monopril group and normal control group (p>0. 05) .?The percentage of cells in GO/G1 phase was remarkably lower in 5% uremic serum group and 10% uremic serum group than in normal control group with use of flow cytometry(p<0. 01), and that was without significant difference between 5% uremic serum group and 10% uremic serum group (p>0. 05) .It was increased significantly in 5% NDQC serum group, 10% NDQC serum group, and monopril group compared with that in 5% uremic serum group (all p<0.01) , and it was not showed significant difference among the fist three group (p>0. 05) .The percentage was lower significantly in 5% NDQC serum group than that in normal control group (p<0.05) ,but No significant difference of the percentage was found among 10% NDQC serum group, monopril group and normal control group (p>0.05) . ?Proliferation index(PI) of HK-2 was increased significantly in 5% uremic serum group , 10% uremic serum group and 5% NDQC serum group than that in normal control group with use of flow cytometry (p<0.01) ,but the PI was without significant difference among 10% NDQC serum group, monopril group and normal control group (p>0. 05) . It was decreased significantly in 5% NDQC serum group, 10% NDQC serum group, and monopril group compared with that in 5% uremic serum group (all p<0.01) .No significant difference of the PI was found among 5% NDQC serum group, 10% NDQC serum group, and monopril group (p>0. 05) . ?The positive percentage of a -SMA
cells was increased significantly in 5% uremic serum group and 10% uremic serum group than that in normal control group with use of flow cytometry (p<0. 01) , but no significant difference between the first two groups (p>0. 05) .It wasn' t decreased significantly in 5% NDQC serum group compared with that in 5% uremic serum group (p>0. 05) , but it was significantly higher in this group than in normal control group (p<0. 01) . The positive percentage was remarkably lower in 10% NDQC serum group and monopril group than in 5% uremic serum group (both p<0. 01) , but higher than in normal control group (p<0. 05) . No significant difference of the positive percentage was found among 5% NDQC serum group, 10% NDQC serum group and monopril group (p>0. 05) . ?The expression of CTGFmRNA was much lower in normal control group than in others (all p<0. 01) , The expression in 10% uremic serum group was highest in all groups (p<0. 01) . No significant difference was found in 5% NDQC serum group compared with that in 5% uremic serum group (p>0. 05) . CTGFmRNA expression was remarkably lower in 10% NDQC serum group and monopril group than in 5% uremic serum group (both p<0.05) . No significant difference of CTGFmRNA expression was found among 5% NDQC serum group, 10% NDQC serum group and monopril group (p>0. 05) . Conclusion: (DThe pathogenesy of renal firosis in CRF is a complicated and interacting network mechanism. Many component elements in the mechanism are not distinct. Most of prevention and cure methods of renal firosis are still in research , and their therapeutic effects are yet dissatisfactory in clinic. TCM has manifested satisfactory anti-renal fibrosis effect and favourable clinical application perspective . (2) NDQC implied 'tonifying and lifting clear QI and excreting turbid pathogen' not only improved clinical symptoms , but also protected renal function, and decreased the fibrotic indexes in CRF patients.All these results show NDQC is a satisfactory inhibitor of renal fibrosis. (3)The mechanism of action of NDQC on renal fibrosis possibly relates to inhibiting cell proliferation and EMT, and preventing cells from synthetizing or secreting fibrotic cytokines. This research result will provide experimental evidence for NDQC s clinical application.
方法:(1)文献研究:通过查阅大量古代和现代中、西医国内外文献,总结和评价有关肾纤维化的中医、西医发病机制和防治措施研究现状。(2)临床研究:用简单随机化、前瞻性的研究方法,将78例慢性肾功能衰竭患者按1∶1分为治疗组和对照组。治疗组用基本治疗加尿毒清胶囊,对照组为基本治疗加包醛氧淀粉,观察患者主要症状、证候(纳差腹胀,恶心呕吐,神疲乏力,腰膝酸痛,皮肤瘙痒,颜面唇甲少华,肌肤甲错,形寒肢冷,手足心热,浮肿,头晕)和实验室检查指标:血红蛋白(Hb)、红细胞总数(RBC)、血清肌酐(Scr)、尿素氮(BUN)、内生肌酐清除率(Ccr)、血清白蛋白(ALB)、血清总胆固醇(Tch)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、血清层粘蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、透明质酸(HA)等,4周为一疗程,连续治疗两个疗程统计结果。继续追踪治疗至6个月时统计各组因病情加重放弃内科治疗,而改用透析治疗的病例数。(3)实验研究:将体外培养人肾小管上皮细胞(HK-2),分为6组:正常对照组、5%尿毒症血清组、10%尿毒症血清组、5%尿毒清胶囊含药血清组、10%尿毒清胶囊含药血清组和蒙诺组(蒙诺浓度为10~(-6)mmol/L),用MTT法检测细胞增殖、用流式细胞术检测细胞周期、a-平滑肌肌动蛋白(α-SMA)阳性细胞的百分率、用逆转录—聚合酶链反应(RT-PCR)测定结缔组织生长因子mRNA(CTGFmRNA)。
结果:(1)文献研究:中医学没有肾纤维化的表述,但根据其临床表现可归于“水肿”、“关格”、“癃闭”、“虚劳”等病症范畴;在病因病机方面,认为脾肾亏虚是本,湿热壅滞三焦,浊毒内盛、瘀血阻络等为标;治疗上多采用通腑泄浊为主,兼用益气补肾、活血化瘀等法。药物有复方制剂、也有单味药物,还有提取的有效单体成分;作用机制有:抑制参与纤维化细胞的增殖和转分化,抑制致纤维化因子的产生、减少ECM的沉积等,表现出较好的疗效。现代医学认为,肾纤维化涉及到肾固有细胞的激活、增殖,单核巨噬细胞的浸润、炎症介质、细胞因子的产生和分泌,最终导致肾脏正常结构的破坏、细胞外基质的沉积,形成纤维化。上皮—间充质细胞转分化(EMT)在肾纤维化中起重要作用,转化生长因子-β1(TGF-β1)和CTGF是强致肾纤维化因子。从防治措施来讲,寻找抑制参与纤维化细胞的增殖和转分化、抑制致纤维化因子的分泌或拮抗其作用的药物,虽然有些用于临床,但疗效不理想。(2)临床研究:治疗组主要症状总积分、大部分症状单项积分均少于对照组(p<0.05或p<0.01),症状有效率和总体疗效高于对照组(p<0.05或p<0.01);尿毒清胶囊能提高慢性肾功能衰竭
Objective: (1)To review the research advancement on the pathogenesy and the therapy of prevention and cure in renal fiabrosis. (2)To observe the clinical efficacy on chronic renal failure(CRF) and the anti-renal fibrosis effect of Chinese traditional medicine Niaoduqing Capsules(NDQC) by the therapy of tonifying and lifting clear QI and excreting pathogenic QI. (3)To explore the mechanism of action of NDQJN on renal fibrosis.Methods:(1)Literature study:To look up a great deal of internal and foreign research documents about the pathogenesy and the therapy of prevention and cure in TCM and western medicine on renal fiabrosis, and summarize and assess these datas. (2)Clinical research:Seventy-eight patients with CRF were randomly and equally divided into subject group and control group .The subject group was administered by symptomatic treatment medicines and NDQC, and the control group was administered by symptomatic treatment medicines and Oxyamyli tectus Aldehydum(OTA). The cardinal symptoms and laboratory examination indexes were observed . The cardinal symptoms included bad appetite, abdominal distension, nausea and vomiting, lassitude, sore waist or knee, skin pruritus, pale face or lip and nails, squamous and dry skin, cold body and limbs, feverish palms and soles, edema, and dizziness. The laboratory examination items contained haematoglobin(HB), red blood cell number(RBC), serum creatinine(Scr), serum urea nitrogen(BUN), creatinine clearance(Ccr), seralbumin(ALB), total cholesterol(Teh), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), serum laminin(LN), precollagen-III(PC-III) , and hyaluronic acid (HA). These items was respectively determined before administration and after eight weeks. The number of patients with dialysis treatment, because of aggravated patient's condition, was recorded in follow-up four months. (3)Experimental study:Human renal tubular epithelial cells (HK-2) were respectively cultured in six different media. They
were normal control group , 5% uremic serum group, 10% uremic serum group, 5% NDQC serum group, 10% NDQC serum group and Monopril geoup(fosinopril density was 10~6mmol/L). Cell proliferation was measured by methylene blue assay (MTT method). Cell life cycle and the positive cell percentage of a-smooth muscle actin(a-SMA) in every group were evaluated by flow cytometry. Connective tissue growth factor messenger RNA (CTGFmRNA) was detected by reverse transcript ion-polymerase chain reaction(RT-PCR) method.Results: (DReview of publications:There was no the nomenclature 'renal fibrosis' in TCM, but the clinical manifestation of renal fibrosis or CRF was discovered in these diseases such as 'edema' , 'frequent vomiting and dysuria' , 'anuria' , 'asthenia' , 'lumbago' and so on. The etiopathogenisis and pathogenesis of renal fibrosis was summarized as asthenia in origin and state of evil domination in superficiality. The asthenia was mainly due to the deficiency of spleen and kidney, and the state of evil domination mainly included stagnation of damp-heat in triple warmer , turbid toxin in body, obstruction of collaterals by blood stasis. The therapeutic methods of cleaning out FU-organ and excreting turbid pathogen were mainly taken , and tonifying QI and invigorating the kidney were also used at the same time in CRF. The materia medica for CRF contained compound preparation, single pharmaceutical product , and simple substance of effective ingredients extracted. Thier mechanisms of action on renal fibrosis were that they inhibited cell proliferation and transdifferentiation , restrained the production of fibrotic factors, and reduced the deposition of extracellular matrix (ECM) in kidney. TCM had satisfactory curative effect on renal fibrosis. At the viewpoint , the pathogenesy of renal fibrosis related to activation and proliferation of renal cells, infiltration of mononuclear macrophage, production and secretion of mediators of inflammation and cytokines. These resulted in destruction of normal kidney structure and deposition of ECM, and fibrous degeneration finally. Epithelium- mesenchymal transdifferentiation(EMT) was one of important pathogenesies in renal fibrosis. Transforming growth factor-P 1(TGF-0 1 ) and CTGF are important growth factor inducing renal fibrosis. People are researching new methods or medicines to prevent and cure renal fibrosis. They may inhibit cell proliferation and EMT , or prevent these cells from secreting or synthesizing cytokines that results in renal fibrosis. Cytokines antagon are also being studied. Some of these medicines have been
administered in some patients, but their therapeutic effect are dissatisfactory. ?The clinical research:The total score of all symptoms and the single score of most of symptoms were both remarkable fewer in subject group than in control group (p<0. 05 UK p<0. 01) .The curative effect rate of symptom and total effective power were both more higher in subject group than in control group(p<0. 05 or p<0. 01) .The levels of ALB and HDL-C were more higher , and the levels of Tchu TG> BUN> Scr> Ccr> LI^ PC-IIL HA were much lower in subject group than in control group(p<0. 05 or p<0. 01) .NDQC remarkably decreased the number of patients who accepted dialytic medication in six months (p<0. 05). ?Experimental study: (DAbsorbance 490(A490) was remarkably higher in 5% uremic serum group and 10% uremic serum group than in normal control group with use of MTT(p<0.01) ,and that was without significant difference between 5% NDQC serum group and 5% uremic serum group (p>0. 05) , and that was much lower both in 10% NDQC serum group and in monopril group than in 5% uremic serum group (both p<0. 01) .No significant difference of A490 was found among 5% NDQC serum group, 10% NDQC serum group, monopril group and normal control group (p>0. 05) .?The percentage of cells in GO/G1 phase was remarkably lower in 5% uremic serum group and 10% uremic serum group than in normal control group with use of flow cytometry(p<0. 01), and that was without significant difference between 5% uremic serum group and 10% uremic serum group (p>0. 05) .It was increased significantly in 5% NDQC serum group, 10% NDQC serum group, and monopril group compared with that in 5% uremic serum group (all p<0.01) , and it was not showed significant difference among the fist three group (p>0. 05) .The percentage was lower significantly in 5% NDQC serum group than that in normal control group (p<0.05) ,but No significant difference of the percentage was found among 10% NDQC serum group, monopril group and normal control group (p>0.05) . ?Proliferation index(PI) of HK-2 was increased significantly in 5% uremic serum group , 10% uremic serum group and 5% NDQC serum group than that in normal control group with use of flow cytometry (p<0.01) ,but the PI was without significant difference among 10% NDQC serum group, monopril group and normal control group (p>0. 05) . It was decreased significantly in 5% NDQC serum group, 10% NDQC serum group, and monopril group compared with that in 5% uremic serum group (all p<0.01) .No significant difference of the PI was found among 5% NDQC serum group, 10% NDQC serum group, and monopril group (p>0. 05) . ?The positive percentage of a -SMA
cells was increased significantly in 5% uremic serum group and 10% uremic serum group than that in normal control group with use of flow cytometry (p<0. 01) , but no significant difference between the first two groups (p>0. 05) .It wasn' t decreased significantly in 5% NDQC serum group compared with that in 5% uremic serum group (p>0. 05) , but it was significantly higher in this group than in normal control group (p<0. 01) . The positive percentage was remarkably lower in 10% NDQC serum group and monopril group than in 5% uremic serum group (both p<0. 01) , but higher than in normal control group (p<0. 05) . No significant difference of the positive percentage was found among 5% NDQC serum group, 10% NDQC serum group and monopril group (p>0. 05) . ?The expression of CTGFmRNA was much lower in normal control group than in others (all p<0. 01) , The expression in 10% uremic serum group was highest in all groups (p<0. 01) . No significant difference was found in 5% NDQC serum group compared with that in 5% uremic serum group (p>0. 05) . CTGFmRNA expression was remarkably lower in 10% NDQC serum group and monopril group than in 5% uremic serum group (both p<0.05) . No significant difference of CTGFmRNA expression was found among 5% NDQC serum group, 10% NDQC serum group and monopril group (p>0. 05) . Conclusion: (DThe pathogenesy of renal firosis in CRF is a complicated and interacting network mechanism. Many component elements in the mechanism are not distinct. Most of prevention and cure methods of renal firosis are still in research , and their therapeutic effects are yet dissatisfactory in clinic. TCM has manifested satisfactory anti-renal fibrosis effect and favourable clinical application perspective . (2) NDQC implied 'tonifying and lifting clear QI and excreting turbid pathogen' not only improved clinical symptoms , but also protected renal function, and decreased the fibrotic indexes in CRF patients.All these results show NDQC is a satisfactory inhibitor of renal fibrosis. (3)The mechanism of action of NDQC on renal fibrosis possibly relates to inhibiting cell proliferation and EMT, and preventing cells from synthetizing or secreting fibrotic cytokines. This research result will provide experimental evidence for NDQC s clinical application.
引文
[1] 阳晓,朱文锋,周小舟,等.慢性肾衰患者不同阶段病机证候特点临床分析[J].中医杂志,2000,41(6):350—352.
[2] 卢玲,梁冰.中医药抗肾纤维化的研究进展.广西中医药,2001,24(6):5-8.
[3] 周静嫒,霍保民.和解法为主治疗慢性肾功能不全的疗效观察.中国中医药信息杂志,1999,(12):34
[4] 王亿平,曹恩泽,吕勇,等.清肾汤治疗慢性肾功能衰竭急剧加重湿热证的疗效观察[J].中西医结合实用临床急救,1999,6(4):154—156.
[5] 晏子友,皮持衡,高书亮,等.化瘀解毒汤对转化生长因子β1及血管紧张素Ⅱ作用的研究.江西中医学院学报.2002,14(2):13-14.
[6] Miyazaki T, Ise M, Hirata M, et al. Kidney Int Suppl, 1997: 63: S211-214.
[7] 刘海燕、刘华锋、何惠娟,等,尿毒血清对人类肾小管上皮细胞增殖及转分化的影响,中国病理生理杂志,2004,20(4):651-654
[8] 刘冠贤,叶任高,谭志明,等.大黄素延缓狼疮性肾炎肾间质纤维化作用的研究.中国实验临床免疫学杂志,1999,11(3):24.
[9] 王晓玲,王俭勤,夏延龄,等.大黄素对人肾成纤维细胞抑制作用的研究.中国中西医结合肾病杂志,2002,3(11):629-631.
[10] 戴春笋,刘志红,陈惠萍,等.大黄酸治疗sTz诱导糖尿病大鼠的远期实验研究.肾脏病与透析肾移植杂志,1999,8(5):413-419.
[11] 程鹏,刘素侠,孙晋浩,等.黄芪抗肝纤维化的作用与转化生长因子β1及干扰素γ的关系.临床军医杂志,2000,28(3):22-23.
[12] 王要军,权启镇,孙自勤,等.黄芪对实验性肝纤维化组织ICAM-1表达影响的免疫组化研究.中国临床药理学与治疗学杂志,2000,5(1):49—51.
[13] 曾治宇,罗心平,施海明,等.黄芪对大鼠心肌梗死后左室胶原的影响.中国急救医学 1999,19(2):86—87.
[14] 陈建,何冰.刘新民,等.银杏叶制剂治疗肺间质纤维化的实验研究.中国中西医结合杂志,2000,20(6):441—443.
[15] 唐锦辉、徐饮儒,刘桐林,等.银杏叶防治大鼠肾小球硬化及肾小管—间质损官的实验研究,中华肾脏病杂志 1998,14(3):174-176.
[16] 郑丰,梁兰青,黎磊石,等.冬虫夏草促进大鼠肾小管细胞增殖与其对庆大霉素急性肾损伤的防治作用.中国病理生理杂志,1995,11(2):211—215.
[17] 方步武,刘平、刘成,等.虫草多糖抗免疫损伤性大鼠肝纤维化的作用及其机理研究,上海中医药杂志,2000,34(9):37-40.
[18] 刘强,侯积寿,马济民,等.虫草影响慢性肾功能衰竭进展的实验研究.中华肾脏病杂志 1995,11(2):81—82.
[19] 许晨,吴兆龙.雷公藤红素防治狼疮性肾炎肾小球硬化的研究.中国中西医结合肾病杂志,2002,3(3):132—135.
[20] 孙万林,刘锐,乔成林,等.纹股蓝总皂甙抗大鼠肾纤维化的实验研究.中国中医药科技,1998,1(5):21-22
[21] 张国强,叶任高,孔庆瑜,等.三七总甙诱导间质纤维化人成纤维细胞凋亡及其分子机制初探.中华肾脏病杂志,1998;14(2):93—95
[22] 杨志云,马琼英.丹参注射液对肾小球系膜细胞增殖及产生IL—6Ⅵ型胶原影响的实验研究.中国中西医结合肾病杂志,2001;2(7):420—421.
[23] 张国强,叶任高,孔庆瑜,等.丹参对LN成纤维细胞增殖,凋亡及C—Myc蛋白表达的影响.中国中西医结合杂志,1997;17(8):473—475.
[24] 傅君舟,蔡桂英,周妙英等.健肾宝冲剂防治肾纤维化临床研究的初步观察.广州医药,2001,32(4):65-67.
[25] 王怡,何立群,郑平东.抗纤灵冲剂对慢性肾衰竭肾功能及纤维化指标影响的临床研究,中国中西医结合肾病杂志,20023(7):396-398.
[26] 王怡,何立群,高建东.抗纤灵颗粒剂改善慢性肾衰竭肾纤维化的研究,中成药,2003,25(10):820-823。
[27] 高峻钰,时振声.大黄蟪虫丸治疗大鼠CRF的实验研究,中国中医药科技,1998;5(2):73-74.
[28] 李福民,熊佩华,符磊,等.活血养阴合剂对大鼠肾小管-间质损害所致CRF作用的实验研究.上海中医药杂志,1998;(11):42—44
[29] 马建伟,刘占民,徐丽梅,等.滋肾活血解毒方对慢性肾衰竭大鼠TGF-β、ET—1的影响.北京中医,2001,(3):45-47.
[30] 朱辟疆,江丽萍,迟雨栩,等.肾衰康延缓CRF进展的实验研究.中国中西医结合肾病杂志,2001;2(9):508-510.
[31] 耿建国,郭立中,刘玉宁,等.温阳利水、化瘀降浊中药对人胎肾小球系膜细胞及细胞外基质抑制作用的实验研究.中国中医药科技,2000;7(4):217—218
[32] 桂华珍,张雅丽,郭兵,等.慢肾康“对纤维化肾组织基质成分的影响.贵阳医学院学报,1999,24(4):369-371.
[33] 李或,牛建昭贺红莉,等,温脾汤对5/6肾切除大鼠残余肾脏影响的实验研究.北京中医药大学学报,2003,26(2):26-28.
[34] 鲁盈,李惊子,郑欣,等.黄芪当归合剂对上肾病综合征血清脂谱和。肾小球硬化的影响、中国中西医结合杂志,1997,17(8):478-480.
[35] 张俊峰.鄂洁,李惊子.黄芪当归合剂对肾病综合征鼠肾转化生长因子β1的影 响.中华肾脏病杂志、1998.8(14):29.
[36] 黄海长,闵亚丽,李惊子等.黄芪当归合剂及依那普利对结缔组织生长因子在肾间质纤维化中表达的比较研究.中华肾脏病杂志,2003,19(3):133-136.
[37] 王荣等,黄芪当归合剂对慢性肾病鼠肾脏细胞表型及MAPK信号转导通路的影响.中国药理学通报,2003,19(9):1069-1074.
[38] 姚晓峰,汤水福,尿毒灵治疗慢性肾功能衰竭的药效学研究.广州中医药大学学报,2003,20(2):157-160.
[39] 高志田,陈以平,庄兴俊.生血肾灵对CRF大鼠肾小球硬化的影响.中国中西医结合肾病杂志,2002,3(2):71—73。
[40] 邓虹珠.陈志良.石兴华,等.中药尿毒清冲剂治疗大鼠慢性肾衰的实验观察.第一军医大学学报.1993,13(1):6.
[41] Nerlich A, Schlecher E. Immunohistochemical localization of extraceeular matrix components in human diabetic glomerular lesions. Am J Pathol, 1991, 139(4): 889.
[42] Kncio GS, Neilson EG, Haverty T, et al. Mechanisms of tubulointerstitial fibrosis. Kidney Int, 1991, 39: 550-556.
[43] 董葆,邹万忠,由江峰.肾小球系膜细胞增生与系膜硬化机制的初步探讨.中华病理学杂志,1994,23(1):10—13.
[44] 张海燕,李幼姬,叶任高等.结缔组织生长因子介导转化生长因子促肾小管上皮细胞转分化.中华肾脏病杂志,2003,19(6):360-364.
[45] Ng YY, Huang TP, Yang WC, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubuloinerstitial fibrosis in 5/6 nephrectomizsed rats. Kidney Int, 1998, 54: 864-876.
[46] Badid C, Vinccm M, Fouque D, et al. Myofibroblast:a pronastic marker and target cell in progressive renal disease. Renal Fail, 2001, 23, 543-549.
[47] 陈香美,喻陆,徐启河.肾脏细胞的活化与慢性进展性肾病.中华肾脏病杂志,2000,16(1):52—54.
[48] Henke C, Marineili W, Jessurun J, et al. Macrophage production of basic fibroblast growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury. Am J Pathol. 1993, 143(4): 1189-99.
[49] Border WA, Noble NA. et al. Transforming growth factor beta in tissue fibrosis. N Engl J Med, 1994, 331: 1286-1292.
[50] Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblast paracrine cells important in health and diseases[J]. Am J physiol, 1999, 12(227): C1—C9.
[51] Coibra T, Wiggins R, Noh JW, et al. TGF-β1 production in antigromerular basement membrane disease in the rabbit[J]. Am J Pathol, 1991, 138: 223-225.
[52] Cohen EP, Bonish SA, Whitehouse E, et al. Mediators and mechanisms of radiation nephropathy[J]. Pro Soc Exp Bio Med, 2000, 223(2): 218-225.
[53] Grotendorst GR. Conecctive tissue growth factor: a mediator of TGF-beta action on fibroblasts[J]. Cytokine Growth Factor Rev, 1997, 8: 171.
[54] Yosimichi G, Nakanishi T, Nishida T, et al. CTGF/Hcs24 induce chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extrocelluar-singnal regulated kinase(ERK)[J]. Eur J Biochem, 2001, 268: 6058.
[55] Murphy M, Godson C, Canon S, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells[J]. Biol Chem, 1999, 274: 5830.
[56] Wahab NA, Yevdokimova N, Weston BS, et al. Role of connective tissue growth factor in the pathogensis of diabetic nephropathy[J]. Biochem J, 2001, 359: 77.
[57] 张杰,屈隧林,王剑勤.大黄素对血管紧张素II刺激人肾成纤维细胞增殖、胶原表达的抑制效应研究.四川医学,2002,23(11):1114—1117.
[58] Liu Yuqing, Zhang Weidong, Guo Aihua, et al. Exression and function of TNF- a in membranoproliferative glomerulophitis[J]. Zhong Guo Xian Dai Yi Xue Za Zhi, 2002, 12(6): 20-23.
[59] Ong AC, Fine LG. Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: implications for human renal disease progression. Am J Kidney Dise, 1994, 23(2): 205-209.
[60] Diamond JR, Levison M, Krisberg R, et al. Increased expression of decorin in experimental hydronephrosis[J]. Kidney Int, Suppl, 1997, 51(4): 1133-1139.
[61] Mizuno S, Mastumoto K, Kuurosawa T, et al. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice[J]. Kidney Int, 2000, 57(3): 937.
[62] Liu BC, Luo DD, Sun J, et al. Influence of irbesartan on renal hypertrophy and thickening of glomerular bacement-membrane in streptozotocin-induced diabetic rats[J]. Zhonghua Nei Ke Za Zhi, 2003, 42: 320.
[63] Banba N, Nakamura T, Matsumuta M, et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int, 2000,58 (2): 684-690.
[64] Simon M, Maresh JG, Harris SE, et al. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol, 1999, 276, F382-F389.
[65] Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol, 2000, 279, F130-F143.
[66] Wang S, Hirschberg R, et al. BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am J Physiol, 2003, (5), F1006-13.
[67] Jurgen BS, Xiulian LZ, Xiaoquan S, et al. Regulation of endothelin production and secetion in cultured collecting duct cells by endogenous transforming growth factor-β[J]. Endocrinology 1996, 37: 5000-5008.
[68] Akgi Y, Isaka Y, Arai M, et al. Inhibition of TGF-β 1 expression by antisense oligonucleotidess suppressed extracellular matrix accumulation in experimental glomerulonephritis[J]. Kindney Int, 1996, 50: 149-155.
[69] Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-β1 antisense oligodeoxynucleotide bkock interstitial fibrosis in unilateral ureteral obstruction[J]. Kidney Int, 2000, 58: 1885-1892.
[70] Yokio H, Sugawara A, Mukoyama M, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-β: A potential target for preventing renal fibrosis[J]. Am J Kindney Dis, 2001, 38(suppl1): S134-138.
[71] Yokio H, Mukoyama M, Sugawara A, et al. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis[J]. Am J Physiol Renal Physiol, 2002, 282: F933-942.
[72] Li M, Chen Y, Zhang Z, et al. Inhibition of mesangial cell proliferation by antisense oligodeoxyneucleotide targeting preproendothelin-1 mRNA in vitro[J]. Chin Med J(Eng-1), 1999, 112: 790-793.
[73] Giampuzzi M, Botti G, Di Duca M, et al. Lysyl oxidase activates the transcricption activity of human coolagene Ⅲ promoter[J]. J Biol Chem, 2000, 275(46): 36341-36349.
[74] Lieber GS, Decarli LM, Mak MK, et al. Attenuations of alcohol induced hepatic fibrosis by polyunsaturated lecithin. Hematology, 1990, 12: 1390-1398.
[75] 郑筱萸.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002.163.
[76] 王海燕,肾脏病学,第二版,北京:人民卫生出版社.2001,2:597.
[77] 王海燕,肾脏病学,第二版,北京:人民卫生出版社.2001,2:1435-1442.
[78] 余江毅,熊宁宁,余承惠.慢性肾病瘀血与湿热病理的临床和实验研究[J].辽宁中医杂志,1995,22(2):91-92.
[79] 季光.乙肝脾胆湿热证与血清HA等的相关性研究,辽宁中医杂志,2000,27(10):433-434
[80] Border WA, Okuds S, Nakamura T, et al. Extracelluler matrix and glomeruler disease. Semin Nephrol, 1989, 9(4): 307-317.
[81] Rohde H, Vargas L, Hahn E, et al. Radioimmunnoassay for type Ⅳ procollagen peptide and its application to human renal disease. Eur J Clin Invest. 1979, 9(6): 451-459.
[82] 卢源,杨里福,马启玲.慢性肾病患者血清透明质酸的测定及其意义.放射免疫学杂志,2002,15(2):111-112
[83] 曹礼应,段建,谢云惠,等.原发性肾小球疾病血清Ⅳ型胶原及LN的意义(J).临床肾脏病杂志,2001,1(1):17-18.
[84] 朱辟疆,韦先进,周逊,等.中药抗纤维化治疗慢性肾衰竭的临床研究.中国中西医结合急救杂志,2002,9(4):206-209
[85] 程新宪,易忠群,李敏,等.血清透明质酸在糖尿病早期肾损害检测中的价值初探.陕西医学杂志,2001,30(6):366-367
[86] 汤水福.尿毒清胶囊对慢性肾功能衰竭的影响及分子机理探讨.广州,广州中医药大学博士学位论文汇编,2004,6.
[87] TWIGG SM, CHEN MM, JOLY AH, et al. Advanced glycosylation end production up-regulate connective tissue growth factor(insulin-like growth factorbinding protein 2) in human fibroblasts: a potential mechanism for expansion of excelluar matrix in diabetes mellitus[J]. Endocrinology, 2001, 142: 1760-1769.
[88] ZeisbergM, KalluriR. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med, 2004, 82: 175-181.
[89] Iwano M. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest, 2002, 110: 341-350.
[90] KalluriR, NeilsonEG. Epithelial-mesenchymaltransition and it simplications for fibrosis. J Clin Invest, 2003, 112: 1776-1784.
[91] Ng YY, Huang TP, Yang WC, et al. Tubular epithelial myofibroblast transdifferentiation in progressive tubulointerstitialfibrosis in 5/6 nephrectomized rats. Kidney Int, 1998, 54: 864-876.
[92] Ito Y, Aten J, Bende R J, et al. Expression of connective tissue growth factor in human renalfibrosis. Kidney Int, 1998, 53: 853-861.
[93] Kumagai H, Katoh S, Hirosawa K, et al. Renaltubulointerstitial injury in weanling rats with hyperhomocysteinemia[J]. Kidney, 2002, 62(4): 1219-1228.
[94] Huang J S, Guh J Y, Chen H C, etal. Role of receptor for advanced glycation end-product(RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells [J]. J Cell Biochem, 2001, 81(1): 102-113.
[95] 刘海燕、刘华锋、何惠娟等,尿毒血清对人类肾小管上皮细胞增殖及转分化的影响,中国病理生理杂志,2004,20(4):651-654。
[96] 刘学耀,洪钦国.尿毒清胶囊治疗45例慢性肾衰疗效分析.中医药学刊,2004,4,22(4):687-688.
[97] 赵青,陈楠,王伟铭,等.结缔组织生长因子在肾间质纤维化中的表达及其意义[J].肾脏病与透析肾移植杂志,2002,11(1):21—25.
[98] Ito Y, Goldschmeding R, Bende R, et al[J]. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol, 2001, 12(3): 472-484.
[99] Hishikawa Z, Oemar BS, Nakaki T, et al[J]. Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem, 2001, 276(20): 16797-16803.
[100] Frazier KS, Paredes A, Dube P. et al. Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol 2000, 37(4): 328-35
[101] 乔青,魏翠英,佟光明等.血液透析对尿毒症患者血清内皮素-1、一氧化氮、血管紧张素的影响及临床意义。中国医药导刊,2004,6:405-408
[102] 罗群,张祖懿,夏兆雄等.不同心功能、心脏结构尿毒症患者血浆心钠素、肾素—血管紧张素系统的变化.浙江医学,1999,21(6):324-327
[103] Iwanciw D, Rehm M, Porst M, et al. Induction of connective tissue growth factor(CTGF)by angiotensin Ⅱ-cooperation of signaling pathways. Nephrol Dial Transplan, 2003, 18(Supplement 4): 285
[104] Wolf G, Kalluri R, Ziyadeh F, etal. Angiotensin Ⅱ induces alpha3(Ⅳ) collagen expression in cultured murine proximal tubular cells. Proc Assoc Am Physicians. 1999, 111(4): 357-64.
[105] Jones SC, Saunders HJ, Pollock CA. High glucose increases growth and co- llagen synthesis in cultured human tubulointerstitial cells. Diabet Med, 1999, 16: 932-938
[106] 陈城,丁国华,尤燕舞.苯那普利对大鼠阿霉素肾病结缔组织生长因子表达的影响.实用医学杂志,2004,20(3):246-248
[2] 卢玲,梁冰.中医药抗肾纤维化的研究进展.广西中医药,2001,24(6):5-8.
[3] 周静嫒,霍保民.和解法为主治疗慢性肾功能不全的疗效观察.中国中医药信息杂志,1999,(12):34
[4] 王亿平,曹恩泽,吕勇,等.清肾汤治疗慢性肾功能衰竭急剧加重湿热证的疗效观察[J].中西医结合实用临床急救,1999,6(4):154—156.
[5] 晏子友,皮持衡,高书亮,等.化瘀解毒汤对转化生长因子β1及血管紧张素Ⅱ作用的研究.江西中医学院学报.2002,14(2):13-14.
[6] Miyazaki T, Ise M, Hirata M, et al. Kidney Int Suppl, 1997: 63: S211-214.
[7] 刘海燕、刘华锋、何惠娟,等,尿毒血清对人类肾小管上皮细胞增殖及转分化的影响,中国病理生理杂志,2004,20(4):651-654
[8] 刘冠贤,叶任高,谭志明,等.大黄素延缓狼疮性肾炎肾间质纤维化作用的研究.中国实验临床免疫学杂志,1999,11(3):24.
[9] 王晓玲,王俭勤,夏延龄,等.大黄素对人肾成纤维细胞抑制作用的研究.中国中西医结合肾病杂志,2002,3(11):629-631.
[10] 戴春笋,刘志红,陈惠萍,等.大黄酸治疗sTz诱导糖尿病大鼠的远期实验研究.肾脏病与透析肾移植杂志,1999,8(5):413-419.
[11] 程鹏,刘素侠,孙晋浩,等.黄芪抗肝纤维化的作用与转化生长因子β1及干扰素γ的关系.临床军医杂志,2000,28(3):22-23.
[12] 王要军,权启镇,孙自勤,等.黄芪对实验性肝纤维化组织ICAM-1表达影响的免疫组化研究.中国临床药理学与治疗学杂志,2000,5(1):49—51.
[13] 曾治宇,罗心平,施海明,等.黄芪对大鼠心肌梗死后左室胶原的影响.中国急救医学 1999,19(2):86—87.
[14] 陈建,何冰.刘新民,等.银杏叶制剂治疗肺间质纤维化的实验研究.中国中西医结合杂志,2000,20(6):441—443.
[15] 唐锦辉、徐饮儒,刘桐林,等.银杏叶防治大鼠肾小球硬化及肾小管—间质损官的实验研究,中华肾脏病杂志 1998,14(3):174-176.
[16] 郑丰,梁兰青,黎磊石,等.冬虫夏草促进大鼠肾小管细胞增殖与其对庆大霉素急性肾损伤的防治作用.中国病理生理杂志,1995,11(2):211—215.
[17] 方步武,刘平、刘成,等.虫草多糖抗免疫损伤性大鼠肝纤维化的作用及其机理研究,上海中医药杂志,2000,34(9):37-40.
[18] 刘强,侯积寿,马济民,等.虫草影响慢性肾功能衰竭进展的实验研究.中华肾脏病杂志 1995,11(2):81—82.
[19] 许晨,吴兆龙.雷公藤红素防治狼疮性肾炎肾小球硬化的研究.中国中西医结合肾病杂志,2002,3(3):132—135.
[20] 孙万林,刘锐,乔成林,等.纹股蓝总皂甙抗大鼠肾纤维化的实验研究.中国中医药科技,1998,1(5):21-22
[21] 张国强,叶任高,孔庆瑜,等.三七总甙诱导间质纤维化人成纤维细胞凋亡及其分子机制初探.中华肾脏病杂志,1998;14(2):93—95
[22] 杨志云,马琼英.丹参注射液对肾小球系膜细胞增殖及产生IL—6Ⅵ型胶原影响的实验研究.中国中西医结合肾病杂志,2001;2(7):420—421.
[23] 张国强,叶任高,孔庆瑜,等.丹参对LN成纤维细胞增殖,凋亡及C—Myc蛋白表达的影响.中国中西医结合杂志,1997;17(8):473—475.
[24] 傅君舟,蔡桂英,周妙英等.健肾宝冲剂防治肾纤维化临床研究的初步观察.广州医药,2001,32(4):65-67.
[25] 王怡,何立群,郑平东.抗纤灵冲剂对慢性肾衰竭肾功能及纤维化指标影响的临床研究,中国中西医结合肾病杂志,20023(7):396-398.
[26] 王怡,何立群,高建东.抗纤灵颗粒剂改善慢性肾衰竭肾纤维化的研究,中成药,2003,25(10):820-823。
[27] 高峻钰,时振声.大黄蟪虫丸治疗大鼠CRF的实验研究,中国中医药科技,1998;5(2):73-74.
[28] 李福民,熊佩华,符磊,等.活血养阴合剂对大鼠肾小管-间质损害所致CRF作用的实验研究.上海中医药杂志,1998;(11):42—44
[29] 马建伟,刘占民,徐丽梅,等.滋肾活血解毒方对慢性肾衰竭大鼠TGF-β、ET—1的影响.北京中医,2001,(3):45-47.
[30] 朱辟疆,江丽萍,迟雨栩,等.肾衰康延缓CRF进展的实验研究.中国中西医结合肾病杂志,2001;2(9):508-510.
[31] 耿建国,郭立中,刘玉宁,等.温阳利水、化瘀降浊中药对人胎肾小球系膜细胞及细胞外基质抑制作用的实验研究.中国中医药科技,2000;7(4):217—218
[32] 桂华珍,张雅丽,郭兵,等.慢肾康“对纤维化肾组织基质成分的影响.贵阳医学院学报,1999,24(4):369-371.
[33] 李或,牛建昭贺红莉,等,温脾汤对5/6肾切除大鼠残余肾脏影响的实验研究.北京中医药大学学报,2003,26(2):26-28.
[34] 鲁盈,李惊子,郑欣,等.黄芪当归合剂对上肾病综合征血清脂谱和。肾小球硬化的影响、中国中西医结合杂志,1997,17(8):478-480.
[35] 张俊峰.鄂洁,李惊子.黄芪当归合剂对肾病综合征鼠肾转化生长因子β1的影 响.中华肾脏病杂志、1998.8(14):29.
[36] 黄海长,闵亚丽,李惊子等.黄芪当归合剂及依那普利对结缔组织生长因子在肾间质纤维化中表达的比较研究.中华肾脏病杂志,2003,19(3):133-136.
[37] 王荣等,黄芪当归合剂对慢性肾病鼠肾脏细胞表型及MAPK信号转导通路的影响.中国药理学通报,2003,19(9):1069-1074.
[38] 姚晓峰,汤水福,尿毒灵治疗慢性肾功能衰竭的药效学研究.广州中医药大学学报,2003,20(2):157-160.
[39] 高志田,陈以平,庄兴俊.生血肾灵对CRF大鼠肾小球硬化的影响.中国中西医结合肾病杂志,2002,3(2):71—73。
[40] 邓虹珠.陈志良.石兴华,等.中药尿毒清冲剂治疗大鼠慢性肾衰的实验观察.第一军医大学学报.1993,13(1):6.
[41] Nerlich A, Schlecher E. Immunohistochemical localization of extraceeular matrix components in human diabetic glomerular lesions. Am J Pathol, 1991, 139(4): 889.
[42] Kncio GS, Neilson EG, Haverty T, et al. Mechanisms of tubulointerstitial fibrosis. Kidney Int, 1991, 39: 550-556.
[43] 董葆,邹万忠,由江峰.肾小球系膜细胞增生与系膜硬化机制的初步探讨.中华病理学杂志,1994,23(1):10—13.
[44] 张海燕,李幼姬,叶任高等.结缔组织生长因子介导转化生长因子促肾小管上皮细胞转分化.中华肾脏病杂志,2003,19(6):360-364.
[45] Ng YY, Huang TP, Yang WC, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubuloinerstitial fibrosis in 5/6 nephrectomizsed rats. Kidney Int, 1998, 54: 864-876.
[46] Badid C, Vinccm M, Fouque D, et al. Myofibroblast:a pronastic marker and target cell in progressive renal disease. Renal Fail, 2001, 23, 543-549.
[47] 陈香美,喻陆,徐启河.肾脏细胞的活化与慢性进展性肾病.中华肾脏病杂志,2000,16(1):52—54.
[48] Henke C, Marineili W, Jessurun J, et al. Macrophage production of basic fibroblast growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury. Am J Pathol. 1993, 143(4): 1189-99.
[49] Border WA, Noble NA. et al. Transforming growth factor beta in tissue fibrosis. N Engl J Med, 1994, 331: 1286-1292.
[50] Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblast paracrine cells important in health and diseases[J]. Am J physiol, 1999, 12(227): C1—C9.
[51] Coibra T, Wiggins R, Noh JW, et al. TGF-β1 production in antigromerular basement membrane disease in the rabbit[J]. Am J Pathol, 1991, 138: 223-225.
[52] Cohen EP, Bonish SA, Whitehouse E, et al. Mediators and mechanisms of radiation nephropathy[J]. Pro Soc Exp Bio Med, 2000, 223(2): 218-225.
[53] Grotendorst GR. Conecctive tissue growth factor: a mediator of TGF-beta action on fibroblasts[J]. Cytokine Growth Factor Rev, 1997, 8: 171.
[54] Yosimichi G, Nakanishi T, Nishida T, et al. CTGF/Hcs24 induce chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extrocelluar-singnal regulated kinase(ERK)[J]. Eur J Biochem, 2001, 268: 6058.
[55] Murphy M, Godson C, Canon S, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells[J]. Biol Chem, 1999, 274: 5830.
[56] Wahab NA, Yevdokimova N, Weston BS, et al. Role of connective tissue growth factor in the pathogensis of diabetic nephropathy[J]. Biochem J, 2001, 359: 77.
[57] 张杰,屈隧林,王剑勤.大黄素对血管紧张素II刺激人肾成纤维细胞增殖、胶原表达的抑制效应研究.四川医学,2002,23(11):1114—1117.
[58] Liu Yuqing, Zhang Weidong, Guo Aihua, et al. Exression and function of TNF- a in membranoproliferative glomerulophitis[J]. Zhong Guo Xian Dai Yi Xue Za Zhi, 2002, 12(6): 20-23.
[59] Ong AC, Fine LG. Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: implications for human renal disease progression. Am J Kidney Dise, 1994, 23(2): 205-209.
[60] Diamond JR, Levison M, Krisberg R, et al. Increased expression of decorin in experimental hydronephrosis[J]. Kidney Int, Suppl, 1997, 51(4): 1133-1139.
[61] Mizuno S, Mastumoto K, Kuurosawa T, et al. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice[J]. Kidney Int, 2000, 57(3): 937.
[62] Liu BC, Luo DD, Sun J, et al. Influence of irbesartan on renal hypertrophy and thickening of glomerular bacement-membrane in streptozotocin-induced diabetic rats[J]. Zhonghua Nei Ke Za Zhi, 2003, 42: 320.
[63] Banba N, Nakamura T, Matsumuta M, et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int, 2000,58 (2): 684-690.
[64] Simon M, Maresh JG, Harris SE, et al. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol, 1999, 276, F382-F389.
[65] Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol, 2000, 279, F130-F143.
[66] Wang S, Hirschberg R, et al. BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am J Physiol, 2003, (5), F1006-13.
[67] Jurgen BS, Xiulian LZ, Xiaoquan S, et al. Regulation of endothelin production and secetion in cultured collecting duct cells by endogenous transforming growth factor-β[J]. Endocrinology 1996, 37: 5000-5008.
[68] Akgi Y, Isaka Y, Arai M, et al. Inhibition of TGF-β 1 expression by antisense oligonucleotidess suppressed extracellular matrix accumulation in experimental glomerulonephritis[J]. Kindney Int, 1996, 50: 149-155.
[69] Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-β1 antisense oligodeoxynucleotide bkock interstitial fibrosis in unilateral ureteral obstruction[J]. Kidney Int, 2000, 58: 1885-1892.
[70] Yokio H, Sugawara A, Mukoyama M, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-β: A potential target for preventing renal fibrosis[J]. Am J Kindney Dis, 2001, 38(suppl1): S134-138.
[71] Yokio H, Mukoyama M, Sugawara A, et al. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis[J]. Am J Physiol Renal Physiol, 2002, 282: F933-942.
[72] Li M, Chen Y, Zhang Z, et al. Inhibition of mesangial cell proliferation by antisense oligodeoxyneucleotide targeting preproendothelin-1 mRNA in vitro[J]. Chin Med J(Eng-1), 1999, 112: 790-793.
[73] Giampuzzi M, Botti G, Di Duca M, et al. Lysyl oxidase activates the transcricption activity of human coolagene Ⅲ promoter[J]. J Biol Chem, 2000, 275(46): 36341-36349.
[74] Lieber GS, Decarli LM, Mak MK, et al. Attenuations of alcohol induced hepatic fibrosis by polyunsaturated lecithin. Hematology, 1990, 12: 1390-1398.
[75] 郑筱萸.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002.163.
[76] 王海燕,肾脏病学,第二版,北京:人民卫生出版社.2001,2:597.
[77] 王海燕,肾脏病学,第二版,北京:人民卫生出版社.2001,2:1435-1442.
[78] 余江毅,熊宁宁,余承惠.慢性肾病瘀血与湿热病理的临床和实验研究[J].辽宁中医杂志,1995,22(2):91-92.
[79] 季光.乙肝脾胆湿热证与血清HA等的相关性研究,辽宁中医杂志,2000,27(10):433-434
[80] Border WA, Okuds S, Nakamura T, et al. Extracelluler matrix and glomeruler disease. Semin Nephrol, 1989, 9(4): 307-317.
[81] Rohde H, Vargas L, Hahn E, et al. Radioimmunnoassay for type Ⅳ procollagen peptide and its application to human renal disease. Eur J Clin Invest. 1979, 9(6): 451-459.
[82] 卢源,杨里福,马启玲.慢性肾病患者血清透明质酸的测定及其意义.放射免疫学杂志,2002,15(2):111-112
[83] 曹礼应,段建,谢云惠,等.原发性肾小球疾病血清Ⅳ型胶原及LN的意义(J).临床肾脏病杂志,2001,1(1):17-18.
[84] 朱辟疆,韦先进,周逊,等.中药抗纤维化治疗慢性肾衰竭的临床研究.中国中西医结合急救杂志,2002,9(4):206-209
[85] 程新宪,易忠群,李敏,等.血清透明质酸在糖尿病早期肾损害检测中的价值初探.陕西医学杂志,2001,30(6):366-367
[86] 汤水福.尿毒清胶囊对慢性肾功能衰竭的影响及分子机理探讨.广州,广州中医药大学博士学位论文汇编,2004,6.
[87] TWIGG SM, CHEN MM, JOLY AH, et al. Advanced glycosylation end production up-regulate connective tissue growth factor(insulin-like growth factorbinding protein 2) in human fibroblasts: a potential mechanism for expansion of excelluar matrix in diabetes mellitus[J]. Endocrinology, 2001, 142: 1760-1769.
[88] ZeisbergM, KalluriR. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med, 2004, 82: 175-181.
[89] Iwano M. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest, 2002, 110: 341-350.
[90] KalluriR, NeilsonEG. Epithelial-mesenchymaltransition and it simplications for fibrosis. J Clin Invest, 2003, 112: 1776-1784.
[91] Ng YY, Huang TP, Yang WC, et al. Tubular epithelial myofibroblast transdifferentiation in progressive tubulointerstitialfibrosis in 5/6 nephrectomized rats. Kidney Int, 1998, 54: 864-876.
[92] Ito Y, Aten J, Bende R J, et al. Expression of connective tissue growth factor in human renalfibrosis. Kidney Int, 1998, 53: 853-861.
[93] Kumagai H, Katoh S, Hirosawa K, et al. Renaltubulointerstitial injury in weanling rats with hyperhomocysteinemia[J]. Kidney, 2002, 62(4): 1219-1228.
[94] Huang J S, Guh J Y, Chen H C, etal. Role of receptor for advanced glycation end-product(RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells [J]. J Cell Biochem, 2001, 81(1): 102-113.
[95] 刘海燕、刘华锋、何惠娟等,尿毒血清对人类肾小管上皮细胞增殖及转分化的影响,中国病理生理杂志,2004,20(4):651-654。
[96] 刘学耀,洪钦国.尿毒清胶囊治疗45例慢性肾衰疗效分析.中医药学刊,2004,4,22(4):687-688.
[97] 赵青,陈楠,王伟铭,等.结缔组织生长因子在肾间质纤维化中的表达及其意义[J].肾脏病与透析肾移植杂志,2002,11(1):21—25.
[98] Ito Y, Goldschmeding R, Bende R, et al[J]. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol, 2001, 12(3): 472-484.
[99] Hishikawa Z, Oemar BS, Nakaki T, et al[J]. Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem, 2001, 276(20): 16797-16803.
[100] Frazier KS, Paredes A, Dube P. et al. Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol 2000, 37(4): 328-35
[101] 乔青,魏翠英,佟光明等.血液透析对尿毒症患者血清内皮素-1、一氧化氮、血管紧张素的影响及临床意义。中国医药导刊,2004,6:405-408
[102] 罗群,张祖懿,夏兆雄等.不同心功能、心脏结构尿毒症患者血浆心钠素、肾素—血管紧张素系统的变化.浙江医学,1999,21(6):324-327
[103] Iwanciw D, Rehm M, Porst M, et al. Induction of connective tissue growth factor(CTGF)by angiotensin Ⅱ-cooperation of signaling pathways. Nephrol Dial Transplan, 2003, 18(Supplement 4): 285
[104] Wolf G, Kalluri R, Ziyadeh F, etal. Angiotensin Ⅱ induces alpha3(Ⅳ) collagen expression in cultured murine proximal tubular cells. Proc Assoc Am Physicians. 1999, 111(4): 357-64.
[105] Jones SC, Saunders HJ, Pollock CA. High glucose increases growth and co- llagen synthesis in cultured human tubulointerstitial cells. Diabet Med, 1999, 16: 932-938
[106] 陈城,丁国华,尤燕舞.苯那普利对大鼠阿霉素肾病结缔组织生长因子表达的影响.实用医学杂志,2004,20(3):246-248